Type 2 & other diabetes

Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention

Cardiovasc DiabetolPublished Retrospective cohort study

Main finding · MACCEsResult — go to the resultHazard ratio 0.96 95% CI 0.89–1.03

Authors' conclusion

In patients undergoing PCI, moderate-intensity statin plus ezetimibe demonstrated a similar risk of MACCEs but a lower risk of new-onset DM than high-intensity statin. Early combination treatment of moderate-intensity statin and ezetimibe may be a useful and safe lipid-lowering strategy after PCI.

Study context

Population
Patients who underwent percutaneous coronary intervention (PCI) from 2012 to 2017, Health Insurance Review and Assessment Service database of South Korea
Participants
45,501 patients7,161 matched pairs
Exposure
Moderate-intensity statin plus ezetimibe vs high-intensity statin
  • Moderate-intensity statin + ezetimiben = 7,161
  • High-intensity statinn = 38,340reference
Outcome
Major adverse cardiac cerebrovascular events (MACCEs): composite of all-cause death, revascularization, or ischemic stroke
Follow-up
Median 2.7 years
Methodological detailsnationwide claims database, propensity-score matched
  • Nationwide claims database
  • Propensity-score matched

Main finding

MACCEs · median follow-up 2.7 years

Hazard ratio

0.96

95% CI 0.89–1.03

P = 0.27

Events by group

Moderate-intensity statin + ezetimibevs High-intensity statin
HR 0.96 (95% CI 0.89–1.03); P = 0.27

As reported in the abstract

Observational data: associations, not effects.

Safety

OutcomeModerate-intensity statin + ezetimibeHigh-intensity statinHR (95% CI)P value
New-onset DMPropensity-score-matched10.7%12.5%0.84 (0.73–0.97)P = 0.02

Original publication

Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. Cardiovasc Diabetol. Published 5 November 2024. doi:10.1186/s12933-024-02498-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.